To include your compound in the COVID-19 Resource Center, submit it here.

Aranesp darbepoetin alfa: Phase I/II data; under review in the U.S. and Europe to treat anemia associated with renal insufficiency or failure

Data from 119 patients in the first 3 dose groups of an open label 177-patient Phase I/II trial showed that

Read the full 206 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers